Cargando…

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. Here, we use TCR sequencing to identify and track alloreactive T cells in a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlap, Garrett S., DiToro, Daniel, Henderson, Joel, Shah, Sujal I., Manos, Mike, Severgnini, Mariano, Weins, Astrid, Guleria, Indira, Ott, Patrick A., Murakami, Naoka, Rao, Deepak A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027853/
https://www.ncbi.nlm.nih.gov/pubmed/36941274
http://dx.doi.org/10.1038/s41467-023-37230-4
_version_ 1784909804853002240
author Dunlap, Garrett S.
DiToro, Daniel
Henderson, Joel
Shah, Sujal I.
Manos, Mike
Severgnini, Mariano
Weins, Astrid
Guleria, Indira
Ott, Patrick A.
Murakami, Naoka
Rao, Deepak A.
author_facet Dunlap, Garrett S.
DiToro, Daniel
Henderson, Joel
Shah, Sujal I.
Manos, Mike
Severgnini, Mariano
Weins, Astrid
Guleria, Indira
Ott, Patrick A.
Murakami, Naoka
Rao, Deepak A.
author_sort Dunlap, Garrett S.
collection PubMed
description Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. Here, we use TCR sequencing to identify and track alloreactive T cells in a patient with melanoma who experienced kidney transplant rejection following PD-1 inhibition. The treatment was associated with a sharp increase in circulating alloreactive CD8(+) T cell clones, which display a unique transcriptomic signature and were also detected in the rejected kidney but not at tumor sites. Longitudinal and cross-tissue TCR analyses indicate unintended expansion of alloreactive CD8(+) T cells induced by ICI therapy for cancer, coinciding with ICI-associated organ rejection.
format Online
Article
Text
id pubmed-10027853
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100278532023-03-22 Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy Dunlap, Garrett S. DiToro, Daniel Henderson, Joel Shah, Sujal I. Manos, Mike Severgnini, Mariano Weins, Astrid Guleria, Indira Ott, Patrick A. Murakami, Naoka Rao, Deepak A. Nat Commun Article Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. Here, we use TCR sequencing to identify and track alloreactive T cells in a patient with melanoma who experienced kidney transplant rejection following PD-1 inhibition. The treatment was associated with a sharp increase in circulating alloreactive CD8(+) T cell clones, which display a unique transcriptomic signature and were also detected in the rejected kidney but not at tumor sites. Longitudinal and cross-tissue TCR analyses indicate unintended expansion of alloreactive CD8(+) T cells induced by ICI therapy for cancer, coinciding with ICI-associated organ rejection. Nature Publishing Group UK 2023-03-21 /pmc/articles/PMC10027853/ /pubmed/36941274 http://dx.doi.org/10.1038/s41467-023-37230-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Dunlap, Garrett S.
DiToro, Daniel
Henderson, Joel
Shah, Sujal I.
Manos, Mike
Severgnini, Mariano
Weins, Astrid
Guleria, Indira
Ott, Patrick A.
Murakami, Naoka
Rao, Deepak A.
Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy
title Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy
title_full Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy
title_fullStr Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy
title_full_unstemmed Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy
title_short Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy
title_sort clonal dynamics of alloreactive t cells in kidney allograft rejection after anti-pd-1 therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027853/
https://www.ncbi.nlm.nih.gov/pubmed/36941274
http://dx.doi.org/10.1038/s41467-023-37230-4
work_keys_str_mv AT dunlapgarretts clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT ditorodaniel clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT hendersonjoel clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT shahsujali clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT manosmike clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT severgninimariano clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT weinsastrid clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT guleriaindira clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT ottpatricka clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT murakaminaoka clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy
AT raodeepaka clonaldynamicsofalloreactivetcellsinkidneyallograftrejectionafterantipd1therapy